RespiQ

RespiQ is a Leiden-based Dutch medtech startup developing AI-enhanced breath analysis technology for disease diagnosis and health management. The company's proprietary molecular sensor technology can detect and quantify volatile biomarkers in breath with high sensitivity and specificity, combining integrated photonics, electronics, and AI algorithms. RespiQ's primary focus is chronic respiratory disease management — particularly COPD — enabling patients to monitor their health via a single breath test and receive personalized insights. The platform also has applications in gut health monitoring (food intolerances via breath) and industrial sensing (leak detection, environmental monitoring). RespiQ secured €4 million in EIC grant funding in 2023 and has received additional early-stage financing from the Netherlands Enterprise Agency (RVO). Partners include Kings College London, SINTEF, LUMC, Amsterdam UMC, and Antler.